Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06689956 · ClinicalTrials.gov registry record

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

A clinical trial of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
212
Enrollment target
20
Study locations

NCT06689956 is a study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 212 participants, above the 170-participant average among 5 other FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06689956, a study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
212 participants
Enrollment target
20
Study locations

Study Summary

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

Interventions

  • OTHER Non-Interventional Study

Study Locations (20)

Other

  • Medical University of Vienna - Vienna
  • AC Camargo Cancer Center - São Paulo
  • Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
  • University Hospital Essen - Essen
  • Meir Medical Center, Faculty of Medicine - Tel-Aviv University - Kefar Sava
  • Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale - Naples
  • Hospital Materno Infantil Las Palmas - Las Palmas
  • Hospital Universitario La Paz - Madrid
  • Ospedale Regionale di Lugano, Civico - Lugano

MI

  • Fondazione IRCCS Istituto Nazionale Tumori - Milan
  • European Institute of Oncology - Milan

Minnesota

  • Mayo Clinic in Rochester - Rochester

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • Houston Methodist Hospital - Houston

Ontario

  • Sunnybrook Health Sciences, University of Toronto - Toronto

Quebec

  • Hopital Maisonneuve Rosemont - Montreal

CN

  • Ospedale Michele e Pietro Ferrero - Verduno

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2024-12-04
Est. Completion 2029-10-31

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06689956

The ClinicalTrials.gov registry entry for NCT06689956 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 170-participant average among 5 other FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (25% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06689956 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, MI, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06689956 about?

NCT06689956 is a clinical study titled "Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study". This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

What is the current status of trial NCT06689956?

This trial is currently recruiting. The enrollment target is 212 participants. The study started on 2024-12-04. Estimated completion is 2029-10-31.

What conditions does trial NCT06689956 study?

This clinical trial studies the following conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023.

What interventions are being tested in trial NCT06689956?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06689956?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06689956 being conducted?

This trial has 20 study locations across Minnesota, New York, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.